A Phase 2A Trial of DT402 for Autism Spectrum Disorder
NCT07303907
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
A Phase 2A Trial of DT402 Open-Label Study in Adults with Autism Spectrum Disorder
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Autism Spectrum Disorder
- ASD
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Definium Therapeutics US, Inc.
- Last updated on ClinicalTrials.gov
- September 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 1
- Spectrum Neuroscience and Treatment Institute · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.